NASDAQ:DAWN Day One Biopharmaceuticals (DAWN) Stock Price, News & Analysis $16.03 +0.15 (+0.94%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$15.79▼$16.3550-Day Range$12.03▼$16.0352-Week Range$9.67▼$18.07Volume487,825 shsAverage Volume889,032 shsMarket Capitalization$1.40 billionP/E RatioN/ADividend YieldN/APrice Target$37.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Day One Biopharmaceuticals alerts: Email Address Day One Biopharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside135.0% Upside$37.67 Price TargetShort InterestBearish19.00% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 11 Articles This WeekInsider TradingSelling Shares$3.37 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.69) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector604th out of 936 stocksPharmaceutical Preparations Industry277th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingDay One Biopharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDay One Biopharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Day One Biopharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.00% of the float of Day One Biopharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDay One Biopharmaceuticals has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Day One Biopharmaceuticals has recently increased by 10.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDay One Biopharmaceuticals does not currently pay a dividend.Dividend GrowthDay One Biopharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DAWN. Previous Next 3.0 News and Social Media Coverage News SentimentDay One Biopharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Day One Biopharmaceuticals this week, compared to 2 articles on an average week.Search Interest3 people have searched for DAWN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows3 people have added Day One Biopharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Day One Biopharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,367,830.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Day One Biopharmaceuticals is held by insiders.Percentage Held by Institutions87.95% of the stock of Day One Biopharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Day One Biopharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Day One Biopharmaceuticals are expected to grow in the coming year, from ($2.69) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Day One Biopharmaceuticals is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Day One Biopharmaceuticals is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDay One Biopharmaceuticals has a P/B Ratio of 4.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Day One Biopharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Day One Biopharmaceuticals Stock (NASDAQ:DAWN)Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Read More DAWN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DAWN Stock News HeadlinesJuly 18, 2024 | insidertrades.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Samuel C. Blackman Sells 20,000 SharesJuly 26 at 3:26 PM | markets.businessinsider.comDay One Biopharmaceuticals Poised for Growth with Strategic Partnerships and Promising Ojemda ProspectsJuly 27, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 26 at 2:20 AM | americanbankingnews.comDay One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Rating of "Moderate Buy" from AnalystsJuly 25 at 3:48 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Day One Biopharmaceuticals (DAWN)July 25 at 5:46 AM | markets.businessinsider.comIpsen Posts Higher H1 Profit, Signs New Partnership With Day One For TovorafenibJuly 25 at 12:58 AM | globenewswire.comIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumorJuly 19, 2024 | americanbankingnews.comInsider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 20,000 Shares of StockJuly 27, 2024 | Monument Traders Alliance (Ad)NEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...July 7, 2024 | seekingalpha.comDay One Biopharmaceuticals: Still Uncertainty After FDA ApprovalMay 30, 2024 | globenewswire.comDay One Announces Sale of Priority Review Voucher for $108 MillionMay 8, 2024 | markets.businessinsider.comBuy Rating for Day One Biopharmaceuticals Amidst DAY101 Approval and Strong Market EntryMay 8, 2024 | markets.businessinsider.comBuy Rating on Day One Biopharmaceuticals: Ojemda’s Market Potential and Strategic CommercializationMay 7, 2024 | finanznachrichten.deDay One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2024 Financial Results and Corporate ProgressMay 7, 2024 | msn.comIndegene IPO subscribed 7.34 times on Day 2May 6, 2024 | globenewswire.comDay One Reports First Quarter 2024 Financial Results and Corporate ProgressMay 4, 2024 | finance.yahoo.comInsider Sale at Day One Biopharmaceuticals Inc (DAWN)April 24, 2024 | msn.comDay One slips despite Ojemda approval as BofA says label “not a home run”See More Headlines Receive DAWN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DAWN CUSIPN/A CIK1845337 Webdayonebio.com Phone650-484-0899FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$37.67 High Stock Price Target$44.00 Low Stock Price Target$33.00 Potential Upside/Downside+135.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-188,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.28% Return on Assets-53.31% Debt Debt-to-Equity RatioN/A Current Ratio10.93 Quick Ratio10.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book4.03Miscellaneous Outstanding Shares87,390,000Free Float80,049,000Market Cap$1.40 billion OptionableOptionable Beta-1.51 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jeremy Bender M.B.A. (Age 53)Ph.D., CEO, President & Director Comp: $900kDr. Samuel C. Blackman M.D. (Age 55)Ph.D., Co-Founder and Head of R&D Comp: $651kMr. Charles N. York II (Age 47)COO, CFO & Secretary Comp: $715kDr. Mike Preigh Ph.D.Chief of Technology OperationsMr. Adam Dubow (Age 57)General Counsel Ms. Jaa RobersonChief People OfficerDr. Davy Chiodin Ph.D.Pharm.D., Chief Development OfficerMs. Lauren Merendino M.B.A. (Age 48)Chief Commercial Officer Dr. Elly Barry M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTMannKindNASDAQ:MNKDLeMaitre VascularNASDAQ:LMATCastle BiosciencesNASDAQ:CSTLBlack Diamond TherapeuticsNASDAQ:BDTXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 6,987 shares on 7/26/2024Ownership: 0.238%Hennion & Walsh Asset Management Inc.Bought 5,070 shares on 7/20/2024Ownership: 0.074%SteelPeak Wealth LLCBought 15,850 shares on 7/17/2024Ownership: 0.018%Samuel C BlackmanSold 20,000 sharesTotal: $320,200.00 ($16.01/share)SG Americas Securities LLCBought 8,222 shares on 7/12/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions DAWN Stock Analysis - Frequently Asked Questions How have DAWN shares performed this year? Day One Biopharmaceuticals' stock was trading at $14.60 at the start of the year. Since then, DAWN shares have increased by 9.8% and is now trading at $16.03. View the best growth stocks for 2024 here. How were Day One Biopharmaceuticals' earnings last quarter? Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) posted its quarterly earnings results on Monday, May, 6th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.05. When did Day One Biopharmaceuticals IPO? Day One Biopharmaceuticals (DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Day One Biopharmaceuticals' major shareholders? Top institutional shareholders of Day One Biopharmaceuticals include Bank of New York Mellon Corp (0.24%), Hennion & Walsh Asset Management Inc. (0.07%), SteelPeak Wealth LLC (0.02%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Ai Day1 Llc, Xi LP Canaan, Samuel C Blackman, Michael Gladstone, Jeremy Bender, Papanek Julie Grant, Julie Papanek Grant, Charles N York II and Pharmaceutical Co Ltd Takeda. View institutional ownership trends. How do I buy shares of Day One Biopharmaceuticals? Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DAWN) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DAWN Stock Alerts